This phase II trial is trying to assess whether combining two immunotherapy drugs (Durvalumab and Tremelimumab) with chemotherapy is more effective than receiving immunotherapy alone, in patients with non-squamous non-small cell (NSC) lung cancer that has spread.
This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
While the combination has been studied in over 200 people, it is not clear if it can offer better results when it is combined with chemotherapy.
Recently, immunotherapies that target the PD-1/PD-L1 axis have shown promise in treating patients with non-small cell lung cancer. Participants will be randomized to receive immunotherapy alone or in combination with a platinum-based chemotherapy drug.
Recruiting Hospitals Read More